Aptevo Therapeutics Inc. APVO
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 12.84% | 20.30% | 15.14% | 12.34% | -6.52% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.64% | 10.66% | 6.95% | 8.51% | -6.36% |
| Operating Income | -10.64% | -10.66% | -6.95% | -8.51% | 6.36% |
| Income Before Tax | -9.92% | -10.77% | -7.61% | -10.24% | 4.84% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -9.92% | -10.77% | -7.61% | -10.24% | 4.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.92% | -10.77% | -7.61% | -11.60% | 3.72% |
| EBIT | -10.64% | -10.66% | -6.95% | -8.51% | 6.36% |
| EBITDA | -11.04% | -11.19% | -7.51% | -9.34% | 5.80% |
| EPS Basic | 62.70% | -- | -- | -- | -- |
| Normalized Basic EPS | 66.08% | -- | -- | -- | -- |
| EPS Diluted | 62.70% | -- | -- | -- | -- |
| Normalized Diluted EPS | 66.08% | -- | -- | -- | -- |
| Average Basic Shares Outstanding | 8,261.46% | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | 8,261.46% | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |